Anavex Life Sciences Corp.
AVXL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.64 | 2.28 | 0.00 | 0.00 |
| FCF Yield | -1.58% | -0.80% | -1.33% | -1.40% |
| EV / EBITDA | -51.31 | 545.92 | -68.90 | -10.14 |
| Quality | ||||
| ROIC | -15.30% | -12.44% | -11.85% | -11.79% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 0.52 | 1.00 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -112.84% | 51.68% | -82.04% | -28.53% |
| Safety | ||||
| Net Debt / EBITDA | 7.57 | -102.91 | 10.53 | 3.89 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |